Subhasree Basu MS. Ph.D. Post-Doc

• Lead multidisciplinary teams for solid tumor bi-specific T cell redirection, ADCC, CDC, ADCP, small molecule, PET Ligand, and ADC programs with a focus on prostate cancer. • Oversee large, multi-million-dollar capital budgets for procurement of Oncology equipment and project budgets. • Manage strategic alliances with external entities on project plans and deliverables. • Facilitate Discovery Team's journey from pre-clinical phase to First in Human clinical trials. • Guide teams from early target identification to New Molecular Entity (NME) declaration • Manage direct and indirect reports in the Oncology Discovery Group and cross-functional teams across R&D • Key Accomplishments: ○ Represented Discovery Team in the Compound Development Team from the pre-clinical phase through the First in Human trials. ○ Led complex R&D plans, defining key steps and elements for achieving objectives. ○ Acquired bio samples from academic partners to develop and validate biomarkers for clinical trial in dose escalation Phase I study. ○ Collaborated extensively with Translational Biomarker Groups to execute strategy and understand tumor antigen expression in patient samples As the team lead for PET Ligand Program- • Oversaw a cross-functional team that included Discovery, CMC, Regulatory, Clinical, Finance, and Medical Affairs teams for PET ligand activities. • Worked in a strategic partnership with three external partners namely, Abzena, Tomopath, and Spectron. • Oversaw a >$5M project budget for the development of the PET ligand. • Worked on analytical method development, formulation and upstream and downstream processes with the CMC team. • Led strategic alliance between the three different external entities on the project plan and deliverables.

Project leader involved in the development of large-molecule immune based redirection programs. Accountable for advancing multiple assets through preclinical development and evaluating new therapeutic platforms. Involved in new target identification efforts through bioinformatics approaches. Supported programs through assay development, optimization and driving external collaborations. Contributed to defining scientific strategies and goals within a project team setting.

Postdoctoral work focussed on- Genetic analysis of p53 tumor suppressor, Impact of p53 SNPs and mutations on cancer disease and cancer cell metabolism and its implications/functions in Genetically modified mouse models. Novel HSP70 inhibitors for melanoma therapy in animal models and human cancer cell lines.

The 6-month program’s comprehensive curriculum provides a full range of managerial insights, including Leadership navigation challenge exercises covering the effective use of managerial power to build trust and motivate people; enhance one's financial and accounting acumen; boost marketing and communications impact; and improve operational and strategic decision-making abilities.

PhD. Thesis work involved- * Investigating signaling pathways that induce cell differentiation/development of tissue. Using the ocular lens as a model- *Discovered that a coordinated α6 integrin/IGF-1R/NFκB survival signal induces expression of survival proteins, which in turn regulates caspase-3 activity during lens epithelial cell differentiation. * Studied mechanisms responsible for inducing autophagy in the ocular lens. Results showed that inhibition of a JNK-regulated mTOR signaled organelle-free zone (OFZ) formation in the lens. Collectively, studies performed revealed essential regulatory mechanisms that control lens differentiation and development. * Published extensively, gave platform and poster presentations at ARVO and ISER. *Led experiments to understand corneal and retinal developmental pathways. *Trained several Undergraduate/Graduate students.